Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis

Documenti analoghi

• Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
  di: David C. Klonoff, et al.
  Pubblicazione: (2024)
• Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
  di: Darren Lau, et al.
  Pubblicazione: (2024)
• One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA
  di: Mengqing Zhang, et al.
  Pubblicazione: (2024)
• Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
  di: Yunwen Xu, et al.
  Pubblicazione: (2025)
• Medication adherence to sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists: A meta‐analysis
  di: Conner E. Johnson, et al.
  Pubblicazione: (2024)